Objective. Тo study the possibility of hyperhomocysteinemia (ННсу) correction in patients with lower extremity artery disease (LEAD) who underwent revascularization with choline and to evaluate its economic effectiveness.

Materials and methods. 94 patients, including 85 (90.4%) men and 9 (9.6%) women participated in the study. The average age of the patients was 62.6±7.7 years. Choline alphoscerate was chosen as the study choline-containing medicine, which was prescribed in a dose of 600 mg twice a day for 10 days.

Homocysteine (Нсу) level was determined by the method of highly-efficient liquid chromatography from the fasting blood plasma of the patients on the 3rd—7th day after the surgery and on the 14th day after taking or absence choline alfoscerate. Hcy concentration was presented in мmol/L.

Results. The patients (n=47) who had taken choline alphoscerate for 10 days formed Group 1. Group 2 (n=47) included those who had not taken this medicine. After undergoing revascularizing surgeries ННсу (15.4±6 мmol/L) was preserved in both groups of the patients. After choline alphoscerate intake there was a statistically significant decrease in Hcy level among group 1 patients: from 13.7±4.2 to 8.9±3.8 мmol/L (p<0.0001). Among the patients who had not taken the stated medicine, Hcy levels remained the same: 17.1±7 and 17.8±7 мmol/L (p=0.62).

The number of complications in group 1 was 3.4 times lower compared with those in group 2. Economic effectiveness between the treatment of the patients in group 1 and group 2 constituted 1037.7 rubles.

Conclusion. Choline alfoscerate intake allows reducing the level of Hcy in patients with LEAD after revascularization, which is reflected in the reduction of post-surgical complications and the number of budget expenditures.